In the press

Richmond acquires Penn

Laboratorios Richmond acquires all the shares of Penn Pharmaceuticals in the amount of 11 million dollars, supporting and accompanying the strategic process of the company to add cardiovascular products to its Central Nervous System line and strengthening its presence in the market of drugs of ambulatory use.
READ MORE

A therapeutic alternative against Alzheimer

On the World Day of the Fight against Alzheimer's, experts recommend exercising the mind, learn new skills and do accompanied activities. Today, in Argentina there are 500,000 people diagnosed with Alzheimer's Disease and while there are no drugs, vaccines or curative therapies to treat it, there is a novel biotechnological compound called Cerebrolysin, developed in Austria, which is already approved and available in our country. A study carried out by a group of 11 physicians and with about 204 patients, showed an improvement in 70% of the cases, primarily in cognition and activities of daily living. On the side of the family and caregivers, data from 197 patients were obtained, yielding a significant improvement in the evaluation of two scales referring to activities of daily living and cognitive impairment. The subjective impression was positive (good and very good) in 77% of cases.
READ MORE

Opening of the new production plant

In August 2011 after an investment of 14 million dollars, the new plant located in Pilar, Buenos Aires, is opened, marking a milestone in the history of the laboratory by allowing deepen its business model. In it are produced drugs in solid oral forms, tablets and capsules, specifically complex and high added value antiretroviral products.
READ MORE

Launch of unique drugs for HIV

Laboratorios Richmond launches SELMIVIR®, combining two widely used active ingredients for treatment of HIV, Lamivudine 300 mg. and Abacavir 600 mg. With the composed fixed dose is achieved a reduction of the number of tablets to be swallowed per day, four (two daily doses of 2 tablets each) to one. This will improve the "compliance" or patient adherence to the antiretroviral therapy. The company also features TAMBUX®, an antibiotic that completes the HIV-AIDS line and contains Rifabutin 150 mg. This drug is specifically indicated for HIV patients co-infected with tuberculosis. The drug presents fewer adverse effects, ensuring greater compliance. Both generic products are the first of its kind in the Argentine market.
READ MORE

First generic for HIV with national development

Laboratorios Richmond launched Mivuten (r), the first generic containing Lamivudine and Tenofovir in combined and fixed-doses, which allows the HIV-Aids treatment to be effective in the long term and preventing virus replication in normal cells, reducing the number of tablets to be taken daily. The combined use of the mentioned drugs is included in the main international guides (USA, WHO) and in the Consensus of the Argentine Infectology Society. To certify the interchangeability of the new product with that combined use, a comparative pharmacokinetics study was conducted in accordance with international resolutions in force, which was approved by the ANMAT.
READ MORE

Alzheimer treatment with Renacenz (Cerebrolysin)

Experts use Renacenz in our country, which drug is Cerebrolysin, to treat Alzheimer's disease or some alteration on vascular dementia. In concordance with international results, significant improvements in cognition or memory have been seen. Also, the effects have been more favorable in 70% of the treated patients in the activities of daily living (eating, walking, bathing, toileting, dressing, etc.)
READ MORE

Donation for over 400 schools

Laboratorios Richmond financially supports the Foundation for Education, Science and Culture (Fundación para la Educación, la Ciencia y la Cultura - FECIC) to produce a documentary on the life of Argentine Nobel Prize Bernardo Houssay. The video will be delivered free of charge to more than 400 secondary schools in the City of Buenos Aires.
READ MORE